Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients

Kelly S. Levano1 | Luis Jaramillo-Valverde1 | David D. Tarazona1 | Cesar Sanchez1 | Silvia Capristano1 | Tania Vásquez-Loarte1 | Lely Solari1 | Alberto Mendoza-Ticona2 | Alonso Soto3,4 | Christian Rojas1 | Roberto Zegarra-Chapoñan1 | Heinner Guio1,5,6

1Instituto Nacional de Salud, Lima, Peru | 2Estrategia Sanitaria Nacional de Prevención y Control de Tuberculosis en el Perú, MINSA, Lima, Peru | 3Instituto de investigación en Ciencias Biomédicas (INICIB), Facultad de Medicina, Universidad Ricardo Palma, Lima, Peru | 4Departamento de Medicina, Hospital Nacional Hipólito Unanue, Lima, Peru | 5Universidad de Huánuco, Huánuco, Peru | 6Universidad Científica del Sur, Lima, Peru

Correspondence
Heinner Guio, Instituto Nacional de Salud, Lima, Peru.
Email: heinnerguio@gmail.com

Abstract

Background: We determined the frequency of genetic polymorphisms in three anti-TB drug metabolic proteins previously reported: N-acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1), and arylacetamide deacetylase (AADAC) within a Peruvian population in a cohort of TB patients.

Methods: We genotyped SNPs rs1041983, rs1801280, rs1799929, rs1799930, rs1208, and rs1799931 for NAT2; rs3813867 and rs2031920 for CYP2E1; and rs1803155 for AADAC in 395 participants completed their antituberculosis treatment.

Results: Seventy-four percent of the participants are carriers of slow metabolizer genotypes: NAT2*5, NAT2*6, and NAT2*7, which increase the sensitivity of INH at low doses and increase the risk of drug-induced liver injuries. Sixty-four percent are homozygous for the wild-type CYP2E1*1A allele, which could increase the risk of hepatotoxicity. However, 16% had a NAT2 fast metabolizer phenotype which could increase the risk of acquiring resistance to INH, thereby increasing the risk of multidrug-resistant (MDR) or treatment failure. The frequency of rs1803155 (AADAC*2 allele) was higher (99.9%) in Peruvians than in European American, African American, Japanese, and Korean populations.

Conclusions: This high prevalence of slow metabolizers for isoniazid in the Peruvian population should be further studied and considered to help individualize drug regimens, especially in countries with a great genetic diversity like Peru. These data will help the Peruvian National Tuberculosis Control Program develop new strategies for therapies.

KEYWORDS
AADAC, CYP2E1, NAT2, tuberculosis
1 | BACKGROUND

Tuberculosis (TB) continues to be a leading cause of global morbidity and mortality, with about 10 million cases and a total of 1.2 million deaths reported in 2019 (“WHO | Global Tuberculosis Report 2019,” 2020). Even though the current TB regimen is highly effective under optimal conditions, there are still many undefined issues including drug underexposure, high prevalence if drug-related toxicity, selection of resistant strains and variability of response (Motta et al., 2018), which could be explained by the variability in the pharmacokinetics of anti-TB drugs. Mutations or polymorphisms in genes encoding metabolic enzymes, transporters, or carriers can lead to this variability in drug pharmacokinetics and pharmacodynamics. The identification of these genetic variations could help select the right anti-TB drug, with the right dosage increasing efficacy and reducing drug-related toxicity and preventing drug resistance (Figueiredo Teixeira et al., 2013; Motta et al., 2018).

To determine if genetic variabilities affecting drug response were present in the Peruvian population, which has a high TB burden with an estimated 32,970 cases in 2019 (“WHO | Global Tuberculosis Report 2019,” 2020), including a high prevalence of drug-resistant TB cases, we determined the frequency of genetic polymorphisms in three anti-TB drug metabolic proteins previously reported: N-acetyltransferase 2 (NAT2) (OMIM #612182), cytochrome P450 2E1 (CYP2E1) (OMIM #124040), and arylacetamide deacetylase (AADAC) (OMIM #600338). These three proteins participate in the metabolism of the initial phase anti-TB drugs: isoniazid and rifampicin. In the liver, isoniazid is acetylated to its major metabolite, N-acetyl-isoniazid by the action of NAT2. It is then further deactivated by other enzymes including CYP2E1 (Bao et al., 2018; Sotsuka et al., 2011). Thus, genetic variations in these two enzymes, leading to alterations in their enzymatic functions can cause variations in isoniazid pharmacokinetics. AADAC is one of the few known enzymes responsible for the deacetylation of rifampicin and AADAC allele decreased enzyme activity (Lee et al., 2019; Nakajima et al., 2011). Thus, genetic variations in these three enzymes, leading to alterations in their enzymatic functions could cause variations in isoniazid and rifampicin pharmacokinetics. For the present study, we selected previously reported single nucleotide polymorphisms (SNPs) that could alter NAT2, CYP2E1, and AADAC enzyme activity and determine their frequency within a Peruvian population in a cohort of TB patients.

2 | PATIENTS AND METHODS

2.1 | Studied populations

Our study includes 395 unrelated individuals diagnosed with pulmonary tuberculosis between 2014 and 2015 recruited from health establishments of the Minister of Health (MINSA) located in Lima and Callao, Peru. The 395 participants (217 males and 178 females) completed their antituberculosis treatment.

2.2 | Genotyping of NAT2, CYP2E1, and AADAC

Genomic DNA was extracted from peripheral blood of all 395 participants using the genomic DNA extraction kit QIAamp DNA Blood Mini Kit (Qiagen). The selected genomic DNA regions for the analysis of each gene included the most common reported SNPs (For NAT2: rs1041983, rs1801280, rs1799929, rs1799930, rs1208, and rs1799931; for CYP2E1: rs3813867 and rs2031920; for AADAC: rs1803155). These regions were amplified by the PCR using Platinum Taq DNA polymerase kit (Invitrogen, USA) using the following primers: For NAT2: 5’-GTCACACAGGGAATCAAATGCT-3’ and 5’-CGTGAGGTAGAGAGATATCTG-3’; for CYP2E1: 5’-CCGTGAGCCAGTCGATGCT-3’ and 5’-TTTCATTCTGCTTCTAACTGCG-3’; and for AADAC: 5’-TCATTCTAGCAGAAGGAGATT-3’ and 5’-GTCACATTTATTCTCTTTGATGATG-3’. PCR-amplified fragments were purified using the QIAGen Gel Purification Kit (Qiagen). SNP genotyping on the purified fragments was performed using Sanger sequencing (Macrogen). Nucleotide substitutions were identified and analyzed using the Geneious version 9.1.5 (Biomatters Ltd.).

2.3 | Computational phenotyping for NAT2

Predicted phenotypes were determined from genotypes as three types of metabolizers: slow metabolizer (two slow alleles), rapid metabolizer (two rapid alleles), and intermediate metabolizer (one slow and another rapid acetylator allele). The alleles considered rapid were: wild-type NAT2*4, 282C>T (NAT2*13), 481C>T (NAT2*11), and 803A>G (NAT2*12), while the alleles considered slow were: 341T>C (NAT2*5), 590G>A (NAT2*6), 857G>A (NAT2*7), and 191G>A (NAT2*14) (Hein et al., 2000). The computational inferred phenotypes using a combination of NAT2 SNPs for the 395 participants were determined using an online software program, NAT2PRED (nat2pred.rit.albany.edu) (Kuznetsov et al., 2009; Sabbagh et al., 2009).

2.4 | Statistical analysis

For phenotypic genotypic and allelic frequencies, 95% confidence intervals were calculated. Data analysis was carried out using Stata 15 program (StataCorp. 2016. Stata Statistical Software: Release 15. College Station, TX, USA).
3  |  RESULTS

In this study, we determined the presence of the six most common SNPs, rs1041983 (282C>T), rs1801280 (341T>C), rs1799929 (481C>T), rs1799930 (590G>A), rs1208 (803A>G), and rs1799931 (857G>A), of the NAT2 gene in the 395 individuals from Lima and Callao, Peru. No new SNPs were identified, indicating that the NAT2 gene has no other SNPs in the Peruvian population studied. The allele frequencies of these major NAT2 SNPs are represented in Table 1. This study found that NAT2*13, C282T, is the most frequent genetic variant (~40% of alleles) among our samples. The allele not harboring any mutation (wild-type NAT2*4) was present in 44 of the 395 samples (~11% of alleles). Table 2 shows the frequencies of NAT2 genotype obtained from the studied population. The most frequent observed heterozygote was also NAT2*13 C282T (48.6%), followed by NAT2*11 C481T (34.9%) and NAT2*5 T341C (34.7%) among the Peruvian population studied. The lowest frequency of observed heterozygote genotypes was NAT2*12 A803G with a frequency of 18.7%. In homozygote, the NAT2*12 803A>G (31.2%) genotype was the most common one but the lowest homozygote among them was NAT2*6 590G>A (12.5%). The linkage disequilibrium (LD) analysis is shown in Figure 1. The six NAT2 variants, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G, and 857G>A were applied to Haploview software. The LD for each pair of genetic variants was measured using |D’| and correlation coefficient (r² > 0.8). A haplotype block was found in the following SNP positions 341T>C and 481C>T (D’: 0.808 and r²: 0.437) in Peruvian population samples which is identified as like strong LD. There were no significant differences observed between NAT2 genotypes with respect to age and gender. The NAT2 inferred metabolizing status was predicted using the six SNPs analyzed as stated above. As a result, the predicted metabolizing phenotype of fast, intermediate, and slow metabolizers was 14.9%, 38.2%, and 46.8%, respectively (Table 3).

The allelic and genotypic distribution of the rs2031920 (~1053C>T) variant of CYP2E1 among the studied population is shown in Tables 1 and 2, respectively. The results show an allele frequency of ~21% for the CYP2E1 variant, and ~79% for the wild-type allele. The observed genotype frequency of the homozygous and heterozygotes were ~7% and ~36%, respectively.

We also analyzed the allele and genotype frequency of the rs1803155 SNP of the AADAC gene in the 395 individuals of this study (Tables 1 and 2). According to our results, the AADAC genetic variant has an allele frequency of ~99.9%, while the wild-type allele was ~20%. The homozygous and heterozygous genotype distribution were ~85% and ~10%, respectively.

4  |  DISCUSSION

Studies in different populations have shown ethnic variabilities in both NAT2 and CYP2E1 genotypes and phenotypes. There is still limited information about the genetic variations in the Peruvian population. In the current study, we analyzed NAT2, CYP2E1, and AADAC genotypes and allele frequencies in 395 individuals from Peru. As stated above, NAT2 and CYP2E1 are two essential enzymes in the metabolism of INH. Altered NAT2 and/or CYP2E1 activities due to polymorphic genotypes can result in (a) the accumulation of toxic substances in the liver, and (b) variations in INH plasma concentrations that can affect the efficacy of the drug.

In the analysis of the NAT2 gene, the results showed that NAT2*13 (39.7% of alleles) and NAT2*7 (35.6% of alleles) were the most frequent genetic variants amount the

| TABLE 1  Allele frequencies of NAT2, CYP2E1, and AADAC polymorphisms in a Peruvian population (n = 395) |
| Gene | Allele (Haplotype) | SNP | Position | Substituted amino acid | Allele frequency (95% CI) |
|------|------------------|-----|----------|------------------------|--------------------------|
| NAT2 | NAT2*4           |     |          | Wild-type              | 0.111 (0.089–0.134)       |
|      | NAT2*13          | rs1041983 | c.282C>T | Y94Y                   | 0.397 (0.363–0.432)       |
|      | NAT2*5           | rs1801280 | c.341T>C | I114T                  | 0.247 (0.216–0.278)       |
|      | NAT2*11          | rs1799929 | c.481C>T | L161L                  | 0.329 (0.296–0.363)       |
|      | NAT2*6           | rs1799930 | c.590G>A | R197Q                  | 0.138 (0.113–0.163)       |
|      | NAT2*12          | rs1208   | c.803A>G | R268K                  | 0.228 (0.198–0.258)       |
|      | NAT2*7           | rs1799931 | c.857G>A | G286E                  | 0.356 (0.322–0.390)       |
| CYP2E1| CYP2E1*1A       |     |          | Wild-type              | 0.79359 (0.765–0.823)     |
|      | CYP2E1*5B        | rs2031920 | c.-1053C>T |                       | 0.206 (0.177–0.235)       |
| AADAC| AADAC*1         |     |          | Wild-type              | 0.199 (0.167–0.230)       |
|      | AADAC*2         | rs1803155 | c.841G>A | V281I                  | 0.999 (0.967–1.03)        |
NAT2*13 is a silent mutation, Y94Y, that does not alter the metabolizer phenotype, whereas NAT2*7 results in an amino acid substitution, G286E, that leads to a significant decrease in the enzyme’s activity (Lakkakula et al., 2014; Vatsis et al., 1991). The distribution of the NAT2 polymorphisms in the population studied were similar to other American populations in that one of the most frequent alleles was NAT2*5 (Table 4). It is established that the frequency of NAT2*5 in European populations is ~50%, in African populations is ~33% to 42% and in Asian populations is ~5% (Borlak & Reamon-Buettner, 2006; Cascorbi et al., 1995; Sekine et al., 2001; Tiis et al., 2020). According to our results, the allele frequency of NAT2*5 is ~25%. The other two slow metabolizer alleles are NAT2*6 and NAT2*7. The NAT2*6 is common in all populations mentioned above with a frequency of ~30%. Conversely, the frequency of NAT2*7 is low in European populations (~2%) and African populations (~3% to 6%). In Asian populations, the frequency of NAT2*7 is ~10% to 12% (Tiis et al., 2020). Diverging from these reports, in our studied population the allele frequency of NAT2*6 is ~14% and of NAT2*7 is ~36%. As stated above, reduced NAT2 activity, which is observed in NAT2*7 variants, can lead to adverse drug reactions due to increased

### TABLE 2
Genotype frequency of NAT2, CYP2E1, and AADAC genes in a Peruvian population (n = 395)

| Gene | Allele | Wild-type frequency (proportion, 95% CI) | Heterozygote frequency (proportion, 95% CI) | Homozygote frequency (proportion, 95% CI) |
|------|--------|----------------------------------------|------------------------------------------|----------------------------------------|
| NAT2 | NAT2*13 (C282T) | C/C: 142 (0.359, 0.312–0.407) | C/T: 192 (0.486, 0.437–0.535) | T/T: 61 (0.154, 0.119–0.190) |
|      | NAT2*5 (T341C) | T/T: 229 (0.580, 0.531–0.628) | T/C: 137 (0.347, 0.300–0.394) | C/C: 29 (0.073, 0.048–0.099) |
|      | NAT2*11 (C481T) | C/C: 196 (0.496, 0.447–0.546) | C/T: 138 (0.349, 0.302–0.396) | T/T: 61 (0.154, 0.119–0.190) |
|      | NAT2*6 (G590A) | G/G: 303 (0.767, 0.725–0.809) | G/A: 75 (0.190, 0.151–0.229) | A/A: 17 (0.043, 0.023–0.063) |
|      | NAT2*12 (A803G) | A/A: 268 (0.678, 0.632–0.725) | A/G: 74 (0.187, 0.149–0.226) | G/G: 53 (0.134, 0.101–0.168) |
|      | NAT2*7 (G857A) | G/G: 210 (0.532, 0.482–0.581) | G/A: 89 (0.225, 0.184–0.267) | A/A: 96 (0.243, 0.201–0.285) |
| CYP2E1 | CYP2E1*5B (C−1053T) | C/C: 250 (0.641, 0.594–0.688) | C/T: 119 (0.359, 0.312–0.406) | T/T: 21 (0.076, 0.032–0.076) |
| AADAC | AADAC*2 (G841A) | G/G: 19 (0.048, 0.027–0.069) | G/A: 41 (0.104, 0.074–0.134) | A/A: 335 (0.848, 0.813–0.883) |

### TABLE 3
Predicted metabolizing phenotype for NAT2 in a Peruvian population (n = 395)

| Gene | Metabolizing phenotype proportion (95% CI) |
|------|----------------------------------------|
| NAT2 | Fast (0.149 (0.114–0.185)) Intermediate (0.382 (0.334–0.430)) Slow (0.468 (0.419–0.518)) |

*The metabolizing phenotype was determined using the online software http://nat2pred.rit.albany.edu/*.

### TABLE 4
Distribution of NAT2 alleles among the Peruvian population studied compared with various human population

| Population | Peru (current study) | Brazil (2016) | Mexico (2012) | Spain (2011) |
|------------|----------------------|---------------|---------------|--------------|
| NAT2*4 (Wild-type) | 0.111 | 0.258 | 0.306 | 0.186 |
| NAT2*13 (C282T) | 0.099 | 0.008 | 0.008 | — |
| NAT2*5 (T341C) | 0.420 | 0.446 | 0.312 | 0.417 |
| NAT2*11 (C481T) | 0.035 | — | — | — |
| NAT2*6 (G590A) | 0.099 | 0.150 | 0.174 | 0.292 |
| NAT2*12 (A803G) | 0.013 | 0.023 | 0.048 | — |
| NAT2*7 (G857A) | 0.223 | 0.096 | 0.140 | 0.106 |
accumulation of toxic metabolites. Additionally, our study revealed that the genotype frequency (predicted phenotype) of slow metabolizers is ~47%. The relationship of NAT2 polymorphisms with INH-induced hepatotoxicity in TB patients among different populations were studied (Azuma et al., 2013; Borlak & Reamon-Buettner, 2006; Cascorbi et al., 1995; Ganachari et al., 2010; Huerta-García et al., 2020; Sekine et al., 2001; Tiis et al., 2020; Zahra et al., 2020), but the previously published studies have demonstrated inconsistent results. Therefore, analysis of the slow genotypes should become part of the dosage regimen of INH in TB patients undergoing anti-TB treatment to prevent drug-induced liver injuries (Azuma et al., 2013; Ganachari et al., 2010; Huerta-García et al., 2020; Zahra et al., 2020).

After NAT2 acetylates INH converting it to acetyl-INH, it can enter the CYP2E1 pathway, which couples with the glutathione-S-transferase (GST) metabolic pathway to facilitate the elimination of toxic metabolites (Guio, Levano, Sánchez, et al., ; Singla et al., 2014; Teixeira et al., 2011). Studies have shown that individuals with the CYP2E1 wild-type allele (c1/c1 genotype) have a higher CYP2E1 activity than those with CYP2E1*5B allele (c1/c2 or c2/c2 genotype). Thus, these individuals can generate more hepatotoxins and therefore increase the risk of drug-induced liver injuries (Huang et al., 2003; Singla et al., 2014; Vuilleumier et al., 2006). In our studied population, the allele frequency of the CYP2E1*5B is ~79%, which increases the risk of hepatotoxicity specially in patients with a slow metabolizer phenotype for NAT2 (Guoua et al., 2014; Singla et al., 2014).

An important enzyme in the metabolism of RIF is AADAC catalyzing its deacetylation to 25-deacetyl-RIF (Nakajima et al., 2011; Png et al., 2012; Thomas et al., 2020). Polymorphic variations affecting this enzyme’s activity can also result in the accumulation of toxic substances and variations in RIF plasma concentrations that can affect the efficacy of this drug. In this study, we analyzed the nonsynonymous SNP rs1803155 (AADAC*2 allele), which leads to a change in amino acid (V281I) in the coding region (Shimizu et al., 2012). An allele frequency of ~60% for AADAC*2 has been reported in European American, African American, Japanese, and Korean populations. In our studied population, the allele frequency of AADAC*2 is ~99.9%. A limitation in this study is the number of SNPs analyzed in each gene, especially in AADAC. The analysis of additional genetic variations in AADAC can provide additional information in the metabolism of RIF. For example, the allele AADAC*3 (g.13651G>A/g.14008T>C), not analyzed in the current study, has shown a reduced metabolizing activity for RIF (Shimizu et al., 2012). Additionally, studies have reported genetic polymorphisms in other RIF metabolizing enzymes, including carboxylesterase 1 (CES1) (OMIM # 114835) and carboxylesterase 2 (CES2) (OMIM # 605278) (Sloan et al., 2017), as well as in drug transporters and/or their transcriptional regulators, including SLCO1B1 (OMIM # 604843) (Yang et al., 2019) and ABCB1 (OMIM # 171050) (Pontual et al., 2017).

Countries have begun clinical trials focused on personalization of tuberculosis treatment to reduce the consequences for patients in treatment (Huerta-García et al., 2020; Yoo et al., 2020). In countries like Peru, where high rates of tuberculosis are recorded and therefore more people in treatment, the pharmacogenomics of individuals becomes a crucial tool for an optimum tuberculosis treatment. This review highlights the importance of having pharmacogenomic studies and having the identification of polymorphisms associated to the metabolism of the antituberculosis drugs in our Peruvian population. Future studies should evaluate adverse effects such as hepatotoxicity and treatment failure.

5 Conclusion

In conclusion, our study showed the distribution of NAT2, CYP2E1, and AADAC genetic polymorphisms in a Peruvian population diagnosed with tuberculosis. This is a preliminary study to help understand the genetic basis of metabolizing polymorphisms in our population, and thus contribute to the use of this and future data in determining the safe INH and RIF dose in slow and fast metabolizers and thus minimizing adverse drug reactions. According to our results, ~74% of the participants are carriers of slow metabolizer genotypes: NAT2*5, NAT2*6, and NAT2*7, which increase the sensitivity of INH at low doses and increase the risk of drug-induced liver injuries. Additionally, ~64% are homozygous for the wild-type CYP2E1*1A allele, which could increase the risk of hepatotoxicity. This high prevalence of slow metabolizers for isoniazid in the Peruvian population should be further studied and considered to help individualize drug regimens, especially in countries with a great genetic diversity like Peru. However, 16% had a NAT2 fast metabolizer phenotype which could increase the risk of acquiring resistance to INH, thereby increasing the risk of multidrug-resistant (MDR) or treatment failure. The frequency of rs1803155 (AADAC*2 allele) was higher (99.9%) in Peruvians than in European American, African American, Japanese, and Korean populations. These data will help the Peruvian National Tuberculosis Control Program develop new strategies for therapies, and in addition, these data are of worldwide interest to identify the distribution of genotypes and allelic frequencies related to the enzymes that participate in the metabolism of antituberculosis drugs.

Acknowledgment

The authors are grateful to all the study participants. This work was supported by the Instituto Nacional de Salud, Lima, Perú.
CONFLICT OF INTEREST
The authors declared no conflict of interest.

AUTHOR CONTRIBUTIONS
Study design: LK, TD, SC, VLT, SL, MTA, SA, RC, and GH. Performed the experiments: LK, JVL, TD, CS, and SCR. Analyzed the data: LK, JVL, TD, VLT, and ZCR. Contributed materials/analysis tools: SC, SL, MTA, SA, RC, and GH. All authors have read and approved the final manuscript.

ETHICAL APPROVAL
Our study was approved by the Ethics in Research Committee of the Peruvian National Institute of Health (INS), and written informed consent was obtained from all the participants.

DATA AVAILABILITY STATEMENT
All data generated or analyzed during this study could be obtained from the authors upon reasonable requirements.

ORCID
Kelly S. Levano https://orcid.org/0000-0001-6519-6305
Luis Jaramillo-Valverde https://orcid.org/0000-0001-5093-6067
David D. Tarazona https://orcid.org/0000-0002-9273-0590
Cesar Sanchez https://orcid.org/0000-0001-7300-0085
Silvia Capristano https://orcid.org/0000-0002-8119-0621
Tania Vásquez-Loarte https://orcid.org/0000-0002-8361-7668
Lely Solari https://orcid.org/0000-0002-8041-8807
Alberto Mendoza-Ticoma https://orcid.org/0000-0002-2571-2894
Alonso Soto https://orcid.org/0000-0001-8648-8032
Roberto Zegarra-Chapoñan https://orcid.org/0000-0002-0471-9413
Heinner Guio https://orcid.org/0000-0003-0078-1188

REFERENCES
Azuma, J., Ohno, M., Kubota, R., Yokota, S., Nagai, T., Tsuyuguchi, K., Okuda, Y., Takashima, T., Kamimura, S., Fujio, Y., & Kawase, I.; Pharmacogenetics-based tuberculosis therapy research group. (2013). NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy. European Journal of Clinical Pharmacology, 69(5), 1091–1101. https://doi.org/10.1007/s00228-012-1429-9
Bao, Y., Ma, X., Rasmussen, T. P., & Zhong, X.-B. (2018). Genetic variations associated with anti-tuberculosis drug-induced liver injury. Current Pharmacology Reports, 4(3), 171–181. https://doi.org/10.1007/s40495-018-0131-8
Borlak, J., & Reamon-Buettner, S. M. (2006). N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Medical Genetics, 7, 58. https://doi.org/10.1186/1471-2350-7-58
Casçorbi, I., Drakoulis, N., Brockmoller, J., Maurer, A., Sperling, K., & Roots, I. (1995). Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. American Journal of Human Genetics, 57(3), 581–592.
de Figueiredo Teixeira, R. L., Pires Lopes, M. Q., Noel, P., & Rezende, A. (2013). Tuberculosis pharmacogenetics: State of the art. In B. H. Mahboub & M. G. Vats (Eds.), Tuberculosis – Current issues in diagnosis and management. Intech. https://doi.org/10.5772/54984
Ganachari, M., Ruiz-Moraes, J. A., da Torre, G., Pretell, J. C., Dinh, J., Granados, J., & Flores-Villanueva, P. O. (2010). Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals. PLoS One, 5(1), e8881. https://doi.org/10.1371/journal.pone.0008881
Guouaou, S., Rabbi, I., Laarabi, F. Z., Elulaoui, S. C., Jaouad, I. C., Barkat, A., & Seifiani, A. (2014). Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genetics, 15, https://doi.org/10.1186/s12863-014-0156-x
Guio, H., Levano, K. S., Sanchez, C., & Tarazona, D. (2015). The role of pharmacogenomics in the tuberculosis treatment regime. Revista Peruana De Medicina Experimental Y Salud Pública, 32(4), 794–800.
Hein, D. W., Doll, M. A., Fretland, A. J., Leff, M. A., Webb, S. J., Xiao, G. H., Devanaboyina, U. S., Nangju, N. A., & Feng, Y. (2000). Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiology, Biomarkers & Prevention, 9(1), 29–42. http://www.ncbi.nlm.nih.gov/pubmed/10667461
Huang, Y. S., Chen, H. D., Su, W. J., Wu, J. C., Chang, S. C., Chiang, C. H., Chang, F. Y., & Lee, S. D. (2003). Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 37(4), 924–930. https://doi.org/10.1053/jhep.2003.50144
Huerta-García, A. P., Medellín-Garibay, S. E., Ortiz-Álvarez, A., Magaña-Aquino, M., Rodríguez-Pinal, C. J., Portales-Pérez, D. P., Romano-Moreno, S., & Milán-Segovia, R. D. C. (2020). Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. International Journal of Clinical Pharmacy, 42(4), 1217–1226. https://doi.org/10.1007/s11096-020-01086-1
Kuznetsov, I. B., Mcduffie, M., & Moslehi, R. (2009). A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. Bioinformatics Applications Note, 9(9), 1185–1186. https://doi.org/10.1093/bioinformatics/btp121
Lee, M.-R., Huang, H.-L., Lin, S.-W., Cheng, M.-H., Lin, Y.-T., Chang, S.-Y., Yan, B.-S., Kuo, C.-H., Lu, P.-L., Wang, J.-Y., & Chong, I.-W. (2019). Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI. Human Genome Variation, 5(1), 1. https://doi.org/10.1038/s41367-019-0052-0
Lakkakula, B. V. K. S., & Maram, R. (2014). NAT2 genetic variations in Mexican patients with tuberculosis. International Journal of Molecular Genetics and Epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiology, Biomarkers & Prevention, 9(1), 29–42. http://www.ncbi.nlm.nih.gov/pubmed/10667461
Lakkakula, S., Pathapati, R. M., Chauhey, G., Munirajan, A. K., Kuznetsov, I. B., Mcduffie, M., & Moslehi, R. (2009). A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. Bioinformatics Applications Note, 9(9), 1185–1186. https://doi.org/10.1093/bioinformatics/btp121
Lakkakula, B. V. K. S., & Maram, R. (2014). NAT2 genetic variations among South Indian populations. Human Genome Variation, 1(1), 1. https://doi.org/10.1038/hgv.2014.14
Lee, M.-R., Huang, H.-L., Lin, S.-W., Cheng, M.-H., Lin, Y.-T., Chang, S.-Y., Yan, B.-S., Kuo, C.-H., Lu, P.-L., Wang, J.-Y., & Chong, I.-W. (2019). Isoniazid concentration and NAT2 genotype predict risk of systemic drug reactions during 3HP for LTBI. Journal of Clinical Medicine, 8(6), 812. https://doi.org/10.3390/jcm8060812
Motta, I., Calcagno, A., & Bonora, S. (2018). Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Expert Opinion on Drug Metabolism & Toxicology, 14(1), 59–82. https://doi.org/10.1080/17425255.2018.1416093
Nakajima, A., Fukushima, Y., Kobayashi, Y., Watanabe, A., Nakajima, M., & Yokoi, T. (2011). Human arylacetamide deacetylase is...
responsible for deacetylation of rifampicin, rifabutin, and rifapentine. *Biochemical Pharmacology*, 82(11), 1747–1756. https://doi.org/10.1016/j.bcp.2011.08.003

Png, E., Alisjahbana, B., Sahiratmadja, E., Marzuki, S., Nelwan, R., Balabanova, Y., Nikolayevsky, V., Drobniewski, F., Nejentsev, S., Adnan, I., van de Vosse, E., Hibberd, M. L., van Crevel, R., Ottenhoff, T. H. M., & Seielstad, M. (2012). A genome wide association study of pulmonary tuberculosis susceptibility in Indonesians. *BMC Medical Genetics*, 13. 5. https://doi.org/10.1186/1471-2350-13-5

Pontual, Y., Pacheco, V. S. S., Monteiro, S. P., Quintana, M. S. B., Costa, M. J. M., Rolla, V. C., & de Castro, L. (2017). ABCB1 gene polymorphism associated with clinical factors can predict drug-resistant tuberculosis. *Clinical Science*, 131(15), 1831–1840. https://doi.org/10.1042/CS20170277

Sabbagh, A., Darlu, P., & Vidaud, M. (2009). Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data. *BMC Medical Genetics*, 10(148), https://doi.org/10.1186/1471-2350-10-148

Sekine, A., Saito, S., Iida, A., Mitsunobu, Y., Higuchi, S., Harigae, Y., & Nakamura, Y. (2001). Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1, and L1CAM in the Japanese population. *Journal of Human Genetics*, 46(6), 314–319. https://doi.org/10.1007/s100380170065

Shimizu, M., Fukami, T., Kobayashi, Y., Takamiya, M., Aoki, Y., Nakajima, M., & Yokoi, T. (2012). A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. *Drug Metabolism and Disposition*, 40(6), 1183–1190. https://doi.org/10.1124/dmd.112.044883

Singla, N., Gupta, D., Birbian, N., & Singh, J. (2014). Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. *Tuberculosis (Edinb)*, 94(3), 293–298. https://doi.org/10.1016/j.tube.2014.02.003

Sloan, D. J., McCallum, A. D., Schipani, A., Egan, D., Mwandumba, H. C., Ward, S. A., Waterhouse, D., Banda, G., Allain, T. J., Owen, A., Khoo, S. H., & Davies, G. R. (2017). Genetic determinants of the pharmacokinetic variability of rifampin in Malawian adults with pulmonary tuberculosis. *Antimicrobial Agents and Chemotherapy*, 61(7), e00210-17. https://doi.org/10.1128/AAC.00210-17

Sotsuka, T., Sasaki, Y., Hirai, S., Yamagishi, F., & Ueno, K. (2011). Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. *Vivo*, 25(5), 803–812.

Teixeira, R. L. D. F., Morato, R. G., Cabello, P. H., Muniz, L. M. K., Moreira, A. D. S. F., Kristki, A. L., Mello, F. C. Q., Sufys, P. N., Miranda, A. B. D., & Santos, A. R. (2011). Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. *Memorias do Instituto Oswaldo Cruz*, 106(6), 716–724. https://doi.org/10.1590/s0074-02762011000600011

Thomas, L., Miraj, S. S., Surulivelrajan, M., Varma, M., Sanju, C. S. V., & Rao, M. (2020). Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients. *Antibiotics*, 9(6), 1–15. https://doi.org/10.3390/antibiotics9060307

Tiis, R. P., Ospova, L. P., Lichman, D. V., Voronina, E. N., & Filipenko, M. L. (2020). Studying polymorphic variants of the NAT2 gene (NAT2*5 and NAT2*7) in Nenets populations of Northern Siberia. *BMC Genetics*, 21(Suppl 1), 115. https://doi.org/10.1186/s12863-020-00909-4

Vatsis, K. P., Martell, K. J., & Weber, W. W. (1991). Diverse point mutations in the human gene for polymorphic N-acetyltransferase. *Proceedings of the National Academy of Sciences of the United States of America*, 88(14), 6333–6337. https://doi.org/10.1073/pnas.88.14.6333

Vuilleumier, N., Rossier, M. F., Chiappe, A., Degoumois, F., Dayer, P., Merrimlod, B., Nicod, L., Desmeules, J., & Hochstrasser, D. (2006). CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. *European Journal of Clinical Pharmacology*, 62(6), 423–429. https://doi.org/10.1007/s00228-006-0111-5

WHO | Global tuberculosis report 2019. (2020). WHO.

Yang, S., Hwang, J. Y., Park, J. Y., Chung, E. K., & Lee, J. I. (2019). Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: A systematic review and meta-analysis. *British Medical Journal Open*. BMJ Publishing Group. 9(8), e027940. http://dx.doi.org/10.1136/bmjopen-2018-027940

Yoo, H., Chun Ji, S., Cho, J.-Y., Kim, S.-H., Yoon, J. G., Goo Lee, M., Yu, K.-S., Jang, I.-J., & Oh, J. (2020). A pilot study to investigate the utility of NAT2 genotype-guided isoniazid mono-therapy regimens in NAT2 slow acetylators. *Pharmacogenetics and Genomics*, 31(3), 68–73. https://doi.org/10.1097/fpc.0000000000000423

Zahra, M. A., Kandel, M., Aldossary, S. A., & Al-Taher, A. (2020). Study on genotyping polymorphism and sequencing of N-acetyltransferase 2 (NAT2) among Al-Ahsa population. *BioMed Research International*, 2020(3), 1–9. https://doi.org/10.1155/2020/876534

How to cite this article: Levano, K. S., Jaramillo-Valverde, L., Tarazona, D. D., Sanchez, C., Capristano, S., Vásquez-Loarte, T., Solari, L., Mendoza-Ticona, A., Soto, A., Rojas, C., Zegarra-Chapaño, R., & Guio, H. (2021). Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients. *Molecular Genetics & Genomic Medicine*, 9, e1764. https://doi.org/10.1002/mgg3.1764